April 28, 2025
Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025
Lead development candidate, AMP-410, is activated only by VEGF signals in tumors and binds to the 4-1BB receptor on immune cells to drive immune response and anti-tumor activity
